Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma

British Journal of Ophthalmology

Volumn 96, Issue 3, 2012, Pages 451-458

  Errington, J A ^a   Conway, R M ^b   Walsh Conway, N ^b   Browning, J ^c   Freyer, C ^c   Cebon, J ^c   Madigan, Michele C ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; GLYCOPROTEIN GP 100; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; MELANOMA ANTIGEN C1; MONOPHENOL MONOOXYGENASE; NY ESO 1 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY LABELING; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CELL DIFFERENTIATION; CELL TYPE; CLINICAL ARTICLE; CONJUNCTIVA DISEASE; CONJUNCTIVAL MELANOMA; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MELANOCYTE; MELANOMA; PRIORITY JOURNAL; TUMOR CELL; TUMOR LOCALIZATION; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CONJUNCTIVAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MELANOMA; MELANOMA-SPECIFIC ANTIGENS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; UVEAL NEOPLASMS;

EID: 84857067030     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2011-300432     Document Type: Article

References (37)

1. Bergman L, Seregard S, Nilsson B, et al. Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci 2002;43:2579-83. (Pubitemid 34809445)
2. Shields CL, Shields JA. Ocular melanoma: relatively rare but requiring respect. Clin Dermatol 2009;27:122-33.
3. Tuomaala S, Eskelin S, Tarkkanen A, et al. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanomas in whites. Invest Ophthalmol Vis Sci 2002;43:3399-408. (Pubitemid 35334346)
4. Kujala E, Tuomaala S, Eskelin S, et al. Mortality after uveal and conjunctival melanoma: which tumour is more deadly? Acta Ophthalmol 2009;87:149-53.
5. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003;44:4651-9. (Pubitemid 37315273)
6. Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009;148:119-27.
7. Augsburger JJ, Correa ZM, Shaikh AH. Quality of evidence about effectiveness of treatments for metastatic uveal melanoma. Trans Am Ophthalmol Soc 2008;106:128-35; discussion 135-7.
8. Sivendran S, Glodny B, Pan M, et al. Melanoma immunotherapy. Mt Sinai J Med 2010;77:620-42.
9. Bosch JJ, Thompson JA, Srivastava MK, et al. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res 2007;67:4499-506. (Pubitemid 46815101)
10. Bosch JJ, Iheagwara UK, Reid S, et al. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8(+) cytotoxic, tumor-specific T cells. Cancer Immunol Immunother 2010;59:103-12.
11. Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-25. (Pubitemid 41081387)
12. Barrow C, Browning J, MacGregor D, et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 2006;12:764-71. (Pubitemid 43259856)
13. Velazquez EF, Jungbluth AA, Yancovitz M, et al. Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)-correlation with prognostic factors. Cancer Immun 2007;7:11-17.
14. Nicholaou T, Ebert LM, Davis ID, et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 2009;15:2166-73.
15. van den Bosch T, Kilic E, Paridaens D, et al. Genetics of uveal melanoma and cutaneous melanoma: two of a kind? Dermatol Res Pract 2010;2010:360136.
16. Gear H, Williams H, Kemp EG, et al. BRAF mutations in conjunctival melanoma. Invest Ophthalmol Vis Sci 2004;45:2484-8. (Pubitemid 38998840)
17. Mulcahy KA, Rimoldi D, Brasseue F, et al. Infrequent expression of the MAGE gene family in uveal melanomas. Int J Cancer 1996;66:738-42. (Pubitemid 26197940)
18. Chen PW, Murray TG, Uno T, et al. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin Exp Metastasis 1996;15:509-18.
19. Luyten GP, van der Spek CW, Brand I, et al. Expression of MAGE, gp100 and tyrosinase genes in uveal melanoma cell lines. Melanoma Res 1998;8:11-16. (Pubitemid 28114296)
20. Chen PW, Murray TG, Salgaller ML, et al. Expression of MAGE genes in ocular melanoma cell lines. J Immunother 1997;20:265-75. (Pubitemid 28011538)
21. Svobodová S, Browning J, MacGregor D, et al. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. Eur J Cancer 2011;47:460-9.
22. Lim E, Browning J, MacGregor D, et al. Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens. Melanoma Res 2006;16:347-55. (Pubitemid 44090179)
23. de Vries TJ, Trancikova D, Ruiter DJ, et al. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. Br J Cancer 1998;78:1156-61. (Pubitemid 28479143)
24. de Vries TJ, Smeets M, de Graaf R, et al. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol 2001;193:13-20. (Pubitemid 32051107)
25. Rosenberg SA, Yang JC, Sherry RM, et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003;14:709-14. (Pubitemid 36623509)
26. Valmori D, Dutoit V, Ayyoub M, et al. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun 2003;3:15-29.
27. Farber M, Schutzer P, Mihm MC Jr. Pigmented lesions of the conjunctiva. J Am Acad Dermatol 1998;38:971-8. (Pubitemid 28299192)
28. Seregard S. Conjunctival melanoma. Surv Ophthalmol 1998;42:321-50. (Pubitemid 28092772)
29. Iwamoto S, Burrows RC, Grossniklaus HE, et al. Immunophenotype of conjunctival melanomas. Comparisons with uveal and cutaneous melanomas. Arch Ophthalmol 2002;120:1625-9. (Pubitemid 36401795)
30. Dratviman-Storobinsky O, Cohen Y, Frenkel S, et al. Lack of oncogenic GNAQ mutations in melanocytic lesions of the conjunctiva as compared to uveal melanoma. Invest Ophthalmol Vis Sci 2010;51:6180-2.
31. Tuomaala S, Toivonen P, Al-Jamal R, et al. Prognostic significance of histopathology of primary conjunctival melanoma in Caucasians. Curr Eye Res 2007;32:939-52. (Pubitemid 350135723)
32. Anassatsiou G, Esser M, Bader E, et al. Expression of cell adhesion molecules and tumour infiltrating leucocytes in conjunctival melanomas. Melanoma Res 2204;14:381-5.
33. Bronkhurst IH, Long LV, Jordanova ES, et al. Detection of M2 macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Sci 2011;52:643-50.
34. Nicholaou T, Ebert L, Davis ID, et al. Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol 2006;8:303-17.
35. Westekemper H, Karimi S, Süsskind D, et al. Expression of MCSP and PRAME in conjunctival melanoma. Br J Ophthalmol 2010;94:1322-7.
36. Moreno-Bost A, Szmania S, Stone K, et al. Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetylase inhibitor MGCD0103. Cytotherapy 2011;13:618-28.
37. Cunneen TS, Conway RM, Madigan MC. In vitro effects of histone deacetylase inhibitors and mitomycin C on tenon capsule fibroblasts and conjunctival melanoma cells. Arch Ophthalmol 2009;127:414-20.